Synta Announces Presentations at the 16th Annual World Conference on Lung Cancer
08 Settembre 2015 - 2:00PM
Business Wire
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that
presentations related to ganetespib, a novel, potent small molecule
inhibitor of heat shock protein 90 (Hsp90) in Phase 3 development,
and STA-12-8666, the Company’s leading candidate from its
proprietary Hsp90 inhibitor Drug Conjugate (HDC) Program, will be
presented at the 16th Annual World Conference on Lung Cancer at the
Colorado Convention Center in Denver, Colorado.
Details of the presentations are provided below:
Mini Oral Presentations:
HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung
Adenocarcinoma Cells and Inhibits Lung Cancer Stem Cells
Date and Time: Tuesday, September 8, 10:45 AM - 12:15 PM
MTLocation: Mile High Ballroom 2c - 3c, MINI14.08Presenter: Vera
Levina, Ph.D., University of Pittsburgh
The Novel HSP90 Inhibitor-SN-38 Conjugate (STA-12-8666), Is
Highly Active in Preclinical Models of Small Cell Lung Cancer
(SCLC)
Date and Time: Wednesday, September 9, 6:30 -8:00 PM MTLocation:
Rooms 605+607, MINI37.02Presenter: Yanis Boumber, M.D., Ph.D.,
University of New Mexico
Poster Presentations:
Ganetespib Resistance in KRAS Mutant NSCLC Is Mediated
through Reactivation of the RAF/MEK/ERK and PI3K/MTOR
Pathways
Date and Time: Tuesday, September 8, 9:30AM – 5:00 PM
MTLocation: Exhibit Hall (Hall B+C), Poster P2.04-101Presenter:
Timothy F. Burns, M.D., University of Pittsburgh
A Phase Ib/II Trial of Doxorubicin with Ganetespib, a Novel
Hsp90 Inhibitor, in Advanced Solid Tumors, with Dose Expansion in
Small Cell Lung Cancer
Date and Time: Wednesday, September 9, 9:30 AM – 5:00 PM
MTLocation: Exhibit Hall (Hall B+C), Poster P3.07-003Presenter:
Deepa Subramaniam, M.D., Georgetown University
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is an innovative, agile
biopharmaceutical company focused on research, development and
commercialization of novel oncology medicines that have the
potential to change the lives of cancer patients. Synta’s lead
oncology drug candidate, ganetespib, a novel heat shock protein 90
(Hsp90) inhibitor, is currently being evaluated in several clinical
trials including the pivotal GALAXY-2 Phase 3 trial in non-small
cell lung cancer. Building on its extensive expertise in the
science of Hsp90, Synta also has a novel proprietary Hsp90
inhibitor Drug Conjugate (HDC) small molecule drug development
program. IND enabling studies have commenced for the first clinical
candidate from the HDC program, STA-12-8666, and preclinical
evaluation of additional HDC candidates is ongoing. For more
information, please visit www.syntapharma.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150908005885/en/
Investors:Synta Pharmaceuticals Corp.Daniel Cole,
781-541-7250dcole@syntapharma.comorArgot PartnersAndrea Rabney,
212-600-1494andrea@argotpartners.comorMedia:Argot
PartnersEliza Schleifstein, 917-763-8106eliza@argotpartners.com
Grafico Azioni Synta Pharmaceuticals Corp. (MM) (NASDAQ:SNTA)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Synta Pharmaceuticals Corp. (MM) (NASDAQ:SNTA)
Storico
Da Nov 2023 a Nov 2024
